RewinD-LB: A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)

What is this study about?

DLB is characterized by progressive dementia, and fluctuating problems with memory and attention. Sleep disturbances, hallucinations, as well as tremors and problems with movement (called Parkinsonism) are also common symptoms. Managing this disease can be difficult and disruptive for both people with DLB and their caregivers. There is no currently approved medication that targets the underlying cause and process of DLB.

This study will evaluate neflamapimod to see if it can improve learning skills, problem solving skills, and memory loss in people with DLB.

What’s involved?

By participating in this study, you can contribute to research and development of an investigational drug candidate.

Participants will complete a screening visit to find out if they qualify for the study. Participants who pass screening and choose to enroll in the study will be assigned to take a neflamapimod capsule or a placebo capsule. Both capsules will look the same, but the placebo has no active ingredients. The assignment is made randomly like flipping a coin. The assigned treatment will be taken 3 times a day for 16 weeks (4 months). During the treatment period, participants will visit the study center for tests and exams 6 times and one additional time after the treatment period ends.

All study participants who complete the initial 16-week period of the study will be able to continue in the study and receive neflamapimod for an additional 32 weeks (8 months), regardless of whether they received neflamapimod or placebo during the first 16 weeks. The extension study will involve an additional 5 study center visits.

Who can participate?

An individual may be able to take part in the study if he/she meets the following qualifications:

  • Men or women who are 55 years or older
  • People who:
    • have probable dementia with Lewy bodies (DLB)
    • have a reliable caregiver who can come to study center visits and help with study procedures and evaluations

This is not a complete list of study requirements. The staff at the study center can explain the complete list of requirements.

Study Sites:


State City Study Site Name Study Contact Email and Phone Number
Arizona Tucson Banner Alzheimer’s Institute Jaynie Anguiano
(520) 694-4154
Arizona Phoenix Barrow Neurological Institute Jalisa Santiago
(602) 406-7851
California Pasadena SC3 Research Group, Inc. Wayne Pickerell
(626) 250-2070
Colorado Aurora University of Colorado Anchutz Medical Campus Nicole Gendelman
(303) 724-4172
Florida Lake Worth JEM Research Institute Angela Rivera
(561) 968-2933
Florida Pensacola Panhandle Research and Medical Clinic, LLC Lynn Jolliff
(850) 619-2926
Kansas Kansas City University of Kansas Medical Center (KUMC) Kim Lee
(913) 588-0013
Louisiana Marrero Tandem Clinical Research Kristin Tassin
(504) 934-8424
Massachusetts Charlestown Massachusetts General Hospital Hannah Webster
(617) 643-5219
North Carolina Chapel Hill University of North Carolina (UNC) John Cherian
(919) 966-1350
Ohio Columbus The Ohio State University (OSU) Seanna Johnson
(614) 293-9023
Virginia Richmond Virginia Commonwealth University (VCU) Kara MaHaney
(804) 828-4788

Contact Person:

Study Sponsor:

EIP Pharma

This study was funded by the National Institute on Aging (NIA)